QUOTE AND NEWS
GenEng News  Mar 30  Comment 
Aduro Biotech launched a collaboration with Novartis to research, develop, and commercialize new immuno-oncology products, under a partnership that could generate up to $750 million for Aduro. The companies committed themselves to developing...
The Hindu Business Line  Mar 29  Comment 
GlaxoSmithKline has reached a deal with the British government to supply a new meningitis B vaccine, following a lengthy stand-off over price with the product's previous owner Novartis.Heal...
FiercePharma  Mar 26  Comment 
It's official: Amgen is appealing last week's ruling in a fight over biosimilar Neupogen. The California-based biotech, aiming to protect its $1.2 billion branded drug, wants to bar Novartis from launching its biosimilar version, Zarxio.
FierceBiotech  Mar 25  Comment 
Novartis became the first to win approval among a scrum of drugmakers with new antibody treatments for autoimmune disease, but its rivals are bounding toward the FDA with positive data of their own.
FierceBiotech  Mar 25  Comment 
Novartis CEO Joseph Jimenez presides over one of the industry's largest R&D budgets, committing about $10 billion a year to drug development. But the American-born executive, in contrast to his predecessor, has made a habit of ditching projects...
FierceBiotech  Mar 24  Comment 
Thomson Reuters is predicting a big year for blockbuster drugs. Its analysts forecast 11 drugs approved this year will go on to rack up blockbuster sales in 2019, with new treatments from Bristol-Myers Squibb, Sanofi and Novartis leading the pack.
FierceBiotech  Mar 24  Comment 
Cambridge, MA, biotech Semma Therapeutics is developing a stem cell technology that could help diabetics return to producing their own insulin, and the nascent company picked up $44 million and a handshake with Novartis to get rolling.
FierceBiotech  Mar 23  Comment 
Austin, Texas, biotech Aeglea Biotherapeutics raised $44 million in Series B cash to bankroll its enzyme-replacement therapy for a rare metabolic disorder, with Eli Lilly and Novartis leading the round.
Benzinga  Mar 20  Comment 
Novartis International AG / New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is...
New York Times  Mar 20  Comment 
Novartis’s drug, Zarxio, contains the same active ingredient as Amgen’s Neupogen, and once released would become the first biosimilar in the United States.




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki